Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CYTOO’s 2D+ Cell Culture Platform Enables Quantitative Mapping

Published: Wednesday, September 19, 2012
Last Updated: Wednesday, September 19, 2012
Bookmark and Share
New applications represent a major step towards quantitative high content analysis of cellular organization in high throughput screening.

CYTOO S.A., has announced new results that demonstrate the ability of the Company’s 2D+ Cell Culture Platform to enable two new high content analysis (HCA) approaches: (i) quantitative density mapping of trafficking compartments and (ii) standardized mitochondrial analysis.

The results will be presented next week at MiPTec 2012 in Basel by the researchers from the Institut Curie in Paris and Angers University Hospital/INSERM, France.

The CYTOO 2D+ Cell Culture Platform, which was launched in July 2012, is based on the use of adhesive micropatterns in microplate wells to guide the cell architecture and behavior in culture.

By defining the 2D topology of cell adhesion, the 2D+ Technology enables the fine control of the spreading and 3D shape of cultured cells in single- or multi-cellular configurations resulting in control of cell contractility, cell polarity, organelle positioning, or cell division axis.

This opens new perspectives for more physiologically relevant cell-based assays compared to classical 2D culture where cells spread and move in an uncontrolled manner.

The researchers of Bruno Goud’s team at the Institut Curie will present at MipTec novel data showing the use of the 2D+ Cell Culture Platform to identify proteins that sustain steady-state organization of trafficking compartments by high-throughput density mapping in several compound and siRNA high content screens.

Following the method developed previously by the team, the hits were selected based on the P-value calculated from the difference between the density map of a pooled control and the density map of each treated condition in the screen.

The data from only 30 cells per condition was sufficient to get statistically significant results.

In comparison, “state-of-the-art” HCA using unrestricted cells with considerable cell-to-cell variation requires hundreds or thousands of cells in order to get significant results.

Arnaud Chevrollier from Angers University Hospital will present the use of the CYTOO 2D+ technology to standardize the quantification of mitochondrial networks in primary skin fibroblasts.

The increasing importance of defective mitochondrial dynamics in several diseases including common neurodegenerative disorders, cardiomyopathies, or age-related disorders, has called for the development of reference imaging tools for medical investigation and drug discovery.

However, until now current approaches to study complex mitochondrial morphology have been limited to low throughput analysis due to the ever varying shape and distribution of the mitochondrial network in cells with heterogeneous size and morphology that is inherent to culture conditions but has no direct biological significance.

The CYTOO 2D+ micropatterned arrays enabled standardization of the size and shape of the cells in culture allowing, for the first time, a high content quantitative relationship between the organization of the mitochondrial network and specific experimental and pathological conditions.

This novel approach can also be applied to high content screening to systematically identify compounds and pathways that impact mitochondrial abundance and sub-cellular distribution.

Commenting on the new results, Michel Bornens, Ph.D, CYTOO Chief Scientific Officer, said: “These two studies to be presented at MiPTec this year demonstrate how, 2D+ Cell Culture Platform enables completely new powerful high content analysis approaches that were previously impossible. We are delighted to see this new data, which represent a major step towards quantitative HCA of cellular organization in high throughput screens.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CYTOO, Cenix BioScience and Academic Collaborators Receive 4 M€ EU FP7 Grant to Launch MEHTRICS Consortium
New public-private consortium to further develop the power of high throughput, high content RNAi screening through convergence with micropatterning-based cell assays.
Monday, December 12, 2011
CYTOO Raises 10 M$ (7M€) in Series C Round
CYTOO to use the financing to fully exploit its fast growing business.
Tuesday, November 29, 2011
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
New Treatment for Rare Blood Cancers
Drug called midostaurin showed promise in an international clinical trial led by a Stanford physician.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!